Implied UBIO Analyst Target Price: $29

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares UltraPro Nasdaq Biotechnology ETF (UBIO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.06 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With UBIO trading at a recent price near $23.39 per unit, that means that analysts see 24.25% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of UBIO's underlying holdings with notable upside to their analyst target prices are Neos Therapeutics Inc ( NEOS), Rigel Pharmaceuticals Inc ( RIGL), and Lion Biotechnologies Inc ( LBIO). Although NEOS has traded at a recent price of $7.10/share, the average analyst target is 308.45% higher at $29.00/share. Similarly, RIGL has 153.85% upside from the recent share price of $2.60 if the average analyst target price of $6.60/share is reached, and analysts on average are expecting LBIO to reach a target price of $16.40/share, which is 146.62% above the recent price of $6.65. Below is a twelve month price history chart comparing the stock performance of NEOS, RIGL, and LBIO:

NEOS, RIGL, and LBIO Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
ProShares UltraPro Nasdaq Biotechnology ETF UBIO $23.39 $29.06 24.25%
Neos Therapeutics Inc NEOS $7.10 $29.00 308.45%
Rigel Pharmaceuticals Inc RIGL $2.60 $6.60 153.85%
Lion Biotechnologies Inc LBIO $6.65 $16.40 146.62%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on NEOS — FREE
Get the latest Zacks research report on RIGL — FREE
Get the latest Zacks research report on LBIO — FREE

More from Stocks

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat